Chasing Absolute Zero In Rheumatoid Arthritis is an active area of clinical research and therapeutic development covered by The Life Science Feed. Our editorial team tracks the latest clinical trials, treatment guidelines, regulatory updates, and scientific advances relevant to Chasing Absolute Zero In Rheumatoid Arthritis. Browse the latest articles below for in-depth analysis and evidence-based clinical insights.
Pediatric CGM OTC: how will you counsel families?
The FDA has cleared the first over-the-counter continuous glucose monitor for children, expanding access to real-time glucose data for pediatric diabetes management.
Treating screwworm: Why an OTC generic is now the frontline
The FDA issued an Emergency Use Authorization for a generic over-the-counter drug to treat New World screwworm infestations in companion animals.
New UV filters' secret: Photostability and broad-spectrum action
The FDA has cleared two new UV filters for sunscreen use, marking the first expansion in two decades. This move aims to broaden consumer choice and align with international standards.
Cell and gene therapy approvals speed up. What does it mean for your practice?
The FDA issued new draft guidance to accelerate cell and gene therapy development, aiming to clarify regulatory pathways and expedite patient access.
How non-animal models are redefining oncology drug safety
The FDA issued draft guidance to reduce animal testing for oncology drugs, allowing sponsors to use non-animal methods for certain safety and efficacy assessments.
Chronic Hepatitis Delta Virus: Why direct viral targeting matters now
The FDA has approved the first treatment for chronic hepatitis delta virus (HDV) infection, addressing a severe form of viral hepatitis with high mortality.
Your patient's child could be exposed to hidden tobacco dangers
The FDA issued warnings to retailers distributing illegal tobacco products designed to resemble common items, posing a significant public health risk, particularly to children.
BHT, ADA, and food chemicals: When 'safe' isn't forever
The FDA finalized its post-market assessment program for food chemicals, immediately launching reassessments of butylated hydroxytoluene (BHT) and adenosine deaminase (ADA). This move signals a shift towards proactive safety evaluations for substances alrea...
Is the future of drug discovery already on your pharmacy shelf?
The FDA is streamlining drug repurposing, leveraging existing data to identify new indications and expedite therapies for unmet medical needs.